Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 2.0 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AstraZeneca; Bayer Healthcare Pharmaceuticals Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb; Celgene Corporation; Lilly; Merck & Co., Inc.; and Pfizer.

Community Practice Connections™ 14th Annual New York Lung Cancer Symposium®

Release Date: January 31, 2020
Expiration Date: January 31, 2021
Media: Internet - based

Activity Overview

Community Practice Connections™: 14th Annual New York Lung Cancers Symposium consists of a series of interactive clinical vignettes, short video interviews of leading experts in lung cancer, and short summaries of clinical data related to these issues. The video interviews address decision points in the clinical vignettes, as well as questions commonly faced in the community oncology practice setting.

Benefits of Participating

  • Learn about cutting-edge applications of immunotherapy in lung cancers.
  • Discuss state-of-the-art approaches for patients with oncogene-driven non–small cell lung cancer (NSCLC).
  • See how experts choose between the increasing therapeutic options in lung cancers.

Acknowledgement of Commercial Support

This activity is supported by educational grants from AstraZeneca; Bayer Healthcare Pharmaceuticals Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb; Celgene Corporation; Lilly; Merck & Co., Inc.; and Pfizer.

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review video files/content until you finish the presentation.
  • At the end of the activity, “Educational Content/Videos” will be available for your reference.
  • In order to receive a CME/CE Certificate, you must complete the activity.
  • Complete the Posttest and the Evaluation, and then click on “Request for Credit.” You may immediately download a CME/CE Certificate upon completion of these steps.

Target Audience

This educational activity is directed toward medical oncologists, surgical oncologists, radiation oncologists, and pulmonologists involved in the treatment of patients with lung cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals (HCPs) interested in the treatment of lung cancer may also participate.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Evaluate testing strategies to optimize tumor characterization and inform clinical decision making for the treatment of patients with lung cancers.
  • Assess emerging clinical evidence regarding the treatment of patients with non-metastatic lung cancer.
  • Describe clinical data concerning single-agent and combination immunotherapeutic approaches to manage lung cancers.
  • Identify current and emerging therapeutic strategies over multiple lines of therapy for patients with oncogene-driven NSCLC subtypes.
  • Evaluate strategies for patients without actionable oncogenic drivers, including the role of chemotherapies and antiangiogenic strategies.
  • Discuss approaches to mitigate and manage treatment-related toxicities in the care of patients with lung cancers.

Faculty, Staff, and Planners’ Disclosures


Mark G. Kris
Mark G. Kris, MD
Attending Physician, Thoracic Oncology Service
William and Joy Ruane Chair in Thoracic Oncology
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosures: Consultant: AstraZeneca, Pfizer, Regeneron.

Roman Perez-Soler
Roman Perez-Soler, MD
Chairman, Department of Oncology
Montefiore Medical Center
Professor of Medicine
Chief, Division of Medical Oncology, Department of Medicine
Deputy Director, Albert Einstein Cancer Center
Bronx, NY

Disclosures: Grant Research Support: National Cancer Institute; Consultant: GlaxoSmithKline, AstraZeneca, Clovis Oncology, Roche/Genentech, Boehringer Ingelheim, Eli Lilly, Adgero Biopharmaceuticals; Shareholder: Stelexis.

Zofia Piotrowska
Zofia Piotrowska, MD
Instructor of Medicine
Harvard Medical School
Assistant in Medicine
Massachusetts General Hospital
Boston, MA

Disclosures: Grant Research Support: AstraZeneca, Novartis, Spectrum Pharmaceuticals, Takeda, Tesaro; Consultant: AstraZeneca, ImmunoGen, Spectrum, Guardant Health, Takeda/ARIAD, Novartis, Genentech, Eli Lilly, Incyte, Medtronic.

Suresh S. Ramalingam
Suresh S. Ramalingam, MD, FACP, FASCO
Roberto C. Goizueta Distinguished Chair for Cancer Research
Deputy Director, Winship Cancer Institute of Emory University
Emory University School of Medicine
Atlanta, GA

Disclosures: Grant Research Support: Tesaro, Merck, AstraZeneca, Advaxis, Bristol-Myers Squibb, Amgen; Consultant: Amgen, AbbVie, Bristol-Myers Squibb, Genentech, Merck, AstraZeneca, Takeda.

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only and is not meant to substitute for the independent clinical judgment of a physician and nurse relative to diagnostic or treatment options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or the company that provided commercial support.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By